Xenograft assays indicated that Deso may block elevated proliferation caused by ZNF131 overexpression and sensitize cisplatin treatment of lung cancer cells in vitro and in vivo (Figure 8K-M). This evidence concerns the gene ZBTB35 and lung carcinoma.